Why farmers are fretting across the worldCapital Audiofest 2024 Highlights, Part 8: VPI, Audio Research, Revox, PureAudioProject, and Luminous Audio Technology - AnalogPlanet.com
Valparaiso hires longtime Marietta coach Andy Waddle to take over its football programExpert Outlook: Agilent Technologies Through The Eyes Of 4 Analysts
‘He brought an aura like no other’ – Tyrone GAA mourns death of legendary player and coach who leaves behind huge legacygeothermal turbines market which was USD 67.61 billion in 2023, would rocket up to USD 111.89 billion by 2031, and is expected to undergo a CAGR of 6.5% 11-22-2024 06:59 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Data Bridge Market Research Private Ltd / PR Agency: Data Bridge Market Research "Global Geothermal Turbines Market, By Type (Flash Steam, Binary Cycle, and Dry Steam), Capacity (Low Capacity (10MW)), Application (Electric Power Generation, Direct Use, and Cogeneration), End Use (Industrial, Residential, Agriculture, and Others) - Industry Trends and Forecast to 2031. Data Bridge Market Research analyses that the global geothermal turbines market which was USD 67.61 billion in 2023, would rocket up to USD 111.89 billion by 2031, and is expected to undergo a CAGR of 6.5% during the forecast period of 2024 to 2031. Explore Further Details about This Research Geothermal Turbines Market Share Report https://www.databridgemarketresearch.com/reports/global-geothermal-turbines-market **Middle East Respiratory Syndrome (MERS) Market Analysis 2021 & 2029** **2021 Analysis:** - The Middle East Respiratory Syndrome (MERS) market in 2021 witnessed steady growth with an increasing focus on research and development efforts to combat the disease. The market was primarily driven by the rising prevalence of MERS infections in the Middle Eastern region, leading to a higher demand for diagnostic tools, treatment options, and preventive measures. The market also saw advancements in technology and innovations in therapeutic approaches to manage MERS. **2029 Analysis:** - By 2029, the Middle East Respiratory Syndrome (MERS) market is projected to experience significant growth due to continued research and development activities aimed at finding more effective treatment modalities and preventive strategies. With an increasing emphasis on public health initiatives and infrastructure development in the Middle East, the market is expected to expand further, offering new opportunities for market players to introduce innovative solutions. **Segments:** - **Diagnostic Tools** - Advanced PCR testing kits - Rapid antigen detection assays - Serology tests - **Treatment Options** - Antiviral medications - Immunomodulators - **Preventive Measures** - Vaccines targeting MERS-CoV - Public health campaigns on hygiene practices **Market Players:** - **Abbott Laboratories** - **Roche Diagnostics** - **Tetracore Inc.** - **Siemens Healthineers** - **Thermo Fisher Scientific** - **Cepheid** - **Fujirebio** - **BioFire Diagnostics** - **Qiagen** - **Biocartis** https://www.databridgemarketresearch.com/reports/global-middle-east-respiratory-syndrome-mers-marketThe Middle East Respiratory Syndrome (MERS) market is poised for significant growth between 2021 and 2029 as key market players continue to invest in research and development efforts to combat the disease effectively. With advancements in technology and therapeutic approaches, there is a growing focus on developing more precise and rapid diagnostic tools to detect MERS infections early on. This emphasis on early detection is crucial in controlling the spread of the disease and reducing the overall burden on healthcare systems in the Middle East region. In terms of treatment options, the market is witnessing a shift towards innovative antiviral medications and immunomodulators that target the specific mechanisms of MERS-CoV, the virus responsible for the syndrome. These novel therapies offer promising outcomes in managing the symptoms of MERS and improving patient outcomes. Additionally, preventive measures such as vaccines targeting MERS-CoV and public health campaigns promoting hygiene practices are becoming increasingly crucial in preventing the spread of the disease and minimizing its impact on public health. Market players such as Abbott Laboratories, Roche Diagnostics, Tetracore Inc., and Siemens Healthineers are at the forefront of developing cutting-edge solutions for the MERS market. These companies are leveraging their expertise in diagnostics, treatment development, and public health initiatives to address the evolving needs of healthcare systems in the Middle East. Collaborative efforts among industry players are also driving innovation and propelling the market forward by introducing new products and solutions that cater to the specific requirements of combating MERS effectively. Moreover, with the growing emphasis on infrastructure development and public health initiatives in the Middle East, there is a ripe opportunity for market players to expand their reach and introduce their offerings to a broader audience. The increasing awareness about MERS and the importance of early detection and treatment among healthcare providers and the general population is creating a conducive environment for market growth. As a result, the Middle East Respiratory Syndrome market is expected to witness a surge in demand for diagnostic tools, treatment options, and preventive measures, presenting lucrative opportunities for**Market Players:** - GeneOne Life Science (South Korea) - INOVIO Pharmaceuticals (U.S.) - Pfizer Inc. (U.S.) - Regeneron Pharmaceuticals Inc (U.S.) - Astellas Pharma Inc. (Japan) - Merck KGaA (Germany) - Sanofi (France) - Biocare Medical, LLC (U.S.) - Lilly (U.S.) - Teva Pharmaceutical Industries Ltd (Israel) The Middle East Respiratory Syndrome (MERS) market is witnessing substantial growth driven by the concerted efforts of key market players in research, development, and innovation. With a focus on developing advanced diagnostic tools, treatment options, and preventive measures, the market is poised to expand significantly between 2021 and 2029. Collaborative efforts among industry leaders such as Abbott Laboratories, Roche Diagnostics, Tetracore Inc., and Siemens Healthineers are paving the way for cutting-edge solutions to combat MERS effectively. These companies are leveraging their expertise to introduce novel therapies, diagnostic kits, and public health initiatives tailored to the unique requirements of the Middle Eastern region. The shift towards more precise diagnostic tools, including PCR testing kits and rapid antigen detection assays, is crucial for early detection of MERS infections, thereby aiding in containing the spread of the disease and reducing the strain on healthcare systems. Additionally, the market is witnessing a transition towards innovative treatment options such as antiviral medications and immunomodulators that target the specific mechanisms of M Table Of Content 1 Introduction 1.1 Objectives Of The Study 1.2 Geothermal Turbines Market Definition 1.3 Overview 1.4 Limitations 1.5 Markets Covered 2 Geothermal Turbines Market Segmentation 2.1 Geothermal Turbines Market Covered 2.2 Geographical Scope 2.3 Years Considered For The Study 2.4 Currency And Pricing 2.5 Dbmr Tripod Data Validation Model 2.6 Multivariate Modeling 2.7 Primary Interviews With Key Opinion Leaders 2.8 Dbmr Geothermal Turbines Market Position Grid 2.9 Dbmr Vendor Share Analysis 2.1 Secondary Sources 2.11 Assumptions 3 Executive Summary............. Browse Related Reports: https://strategicmarketresearch12.blogspot.com/2024/11/glass-substrate-market-driving.html https://strategicmarketresearch12.blogspot.com/2024/11/gasoline-market-trends-in-production.html https://strategicmarketresearch12.blogspot.com/2024/11/frozen-potato-market-increasing-demand.html https://strategicmarketresearch12.blogspot.com/2024/11/hall-effect-current-sensor-market.html Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email: corporatesales@databridgemarketresearch.com About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. This release was published on openPR.
ED attaches 388cr assets in Mahadev online book case
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent payments of up to an aggregate of $4.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of November 25, 2024 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Blue Giant Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and Poseida. The tender offer period will expire at one minute following 11:59 p.m., New York City time on 7 January, 2025, unless the offer is extended. Roche has filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission (SEC). Blue Giant Acquisition Corp. is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer. Poseida has also filed a Solicitation/Recommendation Statement with the SEC on Schedule 14D-9, which includes the unanimous recommendation of the Poseida board of directors that Poseida stockholders tender their shares in the tender offer. Closing of the tender offer is conditioned upon customary closing conditions, including the receipt of required regulatory approvals, and there being validly tendered and not validly withdrawn a majority of the outstanding shares of Poseida common stock. The offer is not subject to any financing condition. Following successful completion of the tender offer, any shares not acquired in the tender offer will be acquired in a second step merger at the same price of $9.00 per share, plus the CVR. The closing of the transaction is expected to take place in the first quarter of 2025. The complete terms and conditions are set out in the Offer to Purchase, which was filed with the SEC today, December 9, 2024. Poseida stockholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC's website (www.sec.gov) or by directing a request for the Solicitation/Recommendation Statement on Schedule 14D-9 to Poseida's website at www.poseida.com or the Offer to Purchase and the other related materials to MacKenzie Partners, Inc., the Information Agent for the offer, toll free at (800) 322-2885 (or please call (212) 929-5500 if you are located outside the U.S. or Canada) or via email at [email protected] . Before making any decision with respect to the Offer, investors are urged to read the Offer to Purchase and related documents, as well as the Solicitation/Recommendation Statement, because they contain important information about the Offer. About Poseida Therapeutics Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumours, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVERTM Site-Specific Gene Editing System Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com . All trademarks used or mentioned in this release are protected by law. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] Phone: +41 79 407 72 58 Phone: +41 79 935 81 48 Phone: +41 79 771 05 25 Phone: +41 79 568 24 95 Phone: +44 797 32 72 915 Phone: +41 79 461 86 83 Phone: +41 79 327 54 74 Phone: +49 172 6367262 Phone: +41 79 961 92 50 Phone: +41 79 205 27 03 Phone: +41 61 68-75284 e-mail: [email protected] Phone: +41 61 68-88027 e-mail: [email protected] Phone: +41 61 68-84814 e-mail: [email protected] Phone: +1 650 225 3217 e-mail: [email protected] This communication may include statements that are not statements of historical fact, or "forward-looking statements,” within the meaning of the federal securities laws, including with respect to Roche's proposed acquisition of Poseida. Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements. These statements are generally identified by words or phrases such as "believe”, "anticipate”, "expect”, "intend”, "plan”, "will”, "may”, "should”, "estimate”, "predict”, "project”, "strategy”, "potential”, "continue” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, the ability of Roche and Poseida to complete the transactions contemplated by the merger agreement, including each party's ability to satisfy the conditions to the consummation of the offer contemplated thereby and the other conditions set forth in the merger agreement and statements about the expected timetable for completing the transaction. These statements are based upon the current beliefs and expectations of Roche and Poseida's management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable if at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements, and you should not place undue reliance on these statements. Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Poseida's stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the offer and the merger contemplated by the merger agreement may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the tender offer or the subsequent merger; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on Poseida's business; the possibility that the milestone payments related to the contingent value right will never be achieved and that no milestone payment may be made; and the risk of legal proceedings being brought in relation to the transactions and the outcome of such proceedings, including the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in Poseida's public filings with the SEC, including the "Risk Factors” section of Poseida's Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q, Form 8-K and in other filings Poseida makes with the SEC from time to time as well as the tender offer materials to be filed by Roche and its acquisition subsidiary and the Solicitation/Recommendation Statement to be filed by Poseida, in each case as amended by any subsequent filings made with the SEC. Neither Roche nor Poseida undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Attachment 09122024_Poseida Trade Offer_enIn a new interview, the scandal-plagued Gaetz reaffirmed his commitment to being a member of Trump’s ‘America First army’. Former United States Congress member Matt Gaetz has confirmed he will not resume his seat in the House of Representatives, amid scrutiny over sex-trafficking allegations. Gaetz had been President-elect Donald Trump’s first pick for the role of attorney general in his incoming administration. But speaking on Friday to the conservative podcast The Charlie Kirk Show, Gaetz addressed his decision to withdraw his name from consideration, as controversy loomed over his nomination. “I think that eight years is probably enough time in the United States Congress,” Gaetz said in the interview. “I’m still going to be in the fight, but it’s going to be from a new perch. I do not intend to join the 119th Congress.” Gaetz, the son of a former Florida state senator, had served as the US representative for Florida’s 1st Congressional District since 2017. But on November 13, when Trump nominated him to lead the Department of Justice, Gaetz abruptly resigned his seat in Congress. Critics pointed out that his resignation came just days before the bipartisan House Ethics Committee was slated to release a report digging into allegations that Gaetz had sex with a minor, engaged in “illicit drug use” and “shared inappropriate images or videos on the House floor”. Gaetz has denied the allegations. But his departure from the House threw the report into limbo, as prominent Republicans argued the committee was only tasked with investigating active members. Democrats, meanwhile, argued the report’s publication was necessary to ensure a transparent and fully informed confirmation process in the Senate. On Wednesday, the committee voted along party lines to withhold the report. By the following day, however, Gaetz announced he would no longer be seeking the attorney general’s position in Trump’s administration. He explained his nomination was “unfairly becoming a distraction” to the goals of the Trump presidency. In Friday’s interview, Gaetz put a positive spin on his brief but fraught nomination. “I know there are people disappointed that I won’t be the next attorney general. But you have to understand: This is the political process, and sometimes the path you’re on is one that takes you to a different place, and it can be a glorious place,” he said. He added that he “enjoyed” his meeting with Republican senators earlier this week, as they discussed the ethics report. Still, he denied that the report played a role in his decision to abandon the confirmation process. “There is a play that is run in Washington when they’re trying to smear somebody. They go and dredge up false, years-old allegations of the most salacious and clickbaity flavour possible,” Gaetz said. “If the things that the House ethics report [said] were true, I would be under indictment and probably in a prison cell. But, of course, they’re false.” He cited his leading role in the removal of former House Speaker Kevin McCarthy in 2023 as stirring up animosity against him. With all the controversy and internal party tensions he faced, Gaetz described his brief stint as the attorney general nominee as akin to “having to do two jobs at one time”. “I had a full-time job explaining to senators that maybe a tweet I said about them was rash and not reflective of how I would serve as attorney general,” Gaetz said. “And at the same time, I was having to build out the Department of Justice with the right human talent, the right policy infrastructure.” One prominent question remained, though: Would Gaetz resume his seat in the House of Representatives? After all, Gaetz had already won re-election on November 5, making him eligible to join the 119th Congress when it gets sworn in early next year. Kirk, the podcast host and prominent conservative activist, put the question to Gaetz. “I’ve been in an elected office for 14 years. I first got elected to the state House when I was 26 years old,” Gaetz responded. “I’m 42 now, and I’ve got some other goals in life that I’m eager to pursue.” He nevertheless underscored his commitment to being part of Trump’s “America First army”. On Thursday, Trump quickly replaced Gaetz as his attorney general nominee with former Florida Attorney General Pam Bondi , another longtime ally. On Friday, Gaetz emphasised that he and Bondi shared the same vision, and he was delighted a fellow Floridian would be his replacement. “My good friend Pam Bondi is going to be a phenomenal attorney general for Donald Trump,” he said. “She has the legal acumen. She hates criminals. She is a bright legal mind and a fellow Floridian. I think that, even though the path will take me to a different station in life and a different place in the fight for our agenda and President Trump, we’ve got a great person in place.”